On Friday, VAALCO Energy, Inc (NYSE:EGY)’s shares gained 0.44% to $2.29, while its weekly performance remained poor, showing the downward trend up to -7.29%, formerly on March 30, VAALCO Energy, Inc.(EGY), declared that the post-salt Kindele-1 well, its first exploration well on Block 5 offshore Angola, was drilled to a total vertical depth of about 1,829 meters. The objective reservoir, the Mucanzo sand formation in the Pinda Group section, was found to be water-bearing and the well is presently in the process of being plugged and abandoned.
Given the results of the well, earlier plans to drill to 2,250 meters for geologic and geophysical correlation will not be undertaken.
As formerly declared in October 2014, VAALCO, together with its working interest partner, Sonangol P&P, reached the Subsequent Exploration Phase (“SEP”) on Block 5. Under the SEP, VAALCO and Sonangol P&P have committed to drill a total of four exploration wells during the exploration extension period, which expires in November 2017. The four-well obligation comprises the original two-well commitment under the primary exploration period that carries over to the SEP period.
VAALCO Energy, Inc., an independent energy corporation, attains, explores for, develops, and produces crude oil and natural gas in the United States. The corporation owns producing properties and conducts exploration activities as an operator of consortiums internationally in Gabon and Angola, in addition to conducts exploration activities as a non-operator in Equatorial Guinea, West Africa.
AngioDynamics, Inc (NASDAQ:ANGO)’s shares dropped -9.42% to $16.53, during the last trading session on Friday, while its weekly performance remained poor, showing the downward trend up to -7.29%, as AngioDynamics, Inc (ANGO), declared a worldwide licensing contract with privately-held EmboMedics Inc., of Minneapolis, Minn., which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in Interventional Radiology, and this newly formed planned relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the about $150 million addressable global embolic market.
“AngioDynamics formerly assisted to build the embolics market, and with worldwide rights to a margin accretive, truly novel technology, we are poised to emulate that success,” said Joseph M. DeVivo, President and Chief Executive Officer of AngioDynamics. “We believe resorbable microspheres represent the future of embolotherapy, allowing for more options in the treatment of patients, and we are excited about the prospect of bringing this technology to our customers worldwide.”
Spherical and compressible, EmboMedics’ technology is designed to break down over time, resulting in reabsorption and elimination by the body. This action may lead to recanalization of the treated arteries, allowing for repeat procedures to occur through the formerly embolized vessels.
AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The corporation offers manifolds, contrast administration systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that assist clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, counting laser system products used in endovascular laser procedures to treat superficial venous diseases, in addition to sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities.
Duke Realty Corp (NYSE:DRE), ended its Friday’s trading session with -0.53% loss, and closed at $20.54, while its weekly performance remained poor, showing the downward trend up to -6.81%, as Duke Realty Corp (DRE), declared the acceptance of notes for purchase following the formerly declared tender offer (the “Tender Offer”) of its operating partnership, Duke Realty Limited Partnership (“Duke Realty”), to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $500,000,000 (the “Maximum Tender Amount”) its 8.25% Senior Notes due 2019 (CUSIP No.: 26441YAT4) (the “2019 Notes”), its 5.95% Senior Notes due 2017 (CUSIP No.: 26441YAM9) (the “2017 Notes”), its 6.75% Senior Notes due 2020 (CUSIP No.: 26441YAU1) (the “2020 Notes”), its 6.50% Senior Notes due 2018 (CUSIP No.: 26441YAQ0) (the “2018 Notes”) and its 4.375% Senior Notes due 2022 (CUSIP No.: 26441YAV9) (the “2022 Notes”). The 2019 Notes, the 2017 Notes, the 2020 Notes, the 2018 Notes and the 2022 Notes are referred to collectively as the “Securities.”
Duke Realty Corporation operates as a real estate investment trust (REIT) in the United States. It offers leasing, property and asset administration, development, construction, build-to-suit, and other tenant-related services. As of December 31, 2006, Duke Realty owned about 721 industrial, office, and retail properties comprising 113.8 million rentable square feet, in addition to owned 6,400 acres of unencumbered land for development.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
